Agile Therapeutics Inc Capitalisation boursière

Quel est le Capitalisation boursière de Agile Therapeutics Inc?

Le Capitalisation boursière de Agile Therapeutics Inc est $23.60M

Quelle est la définition de Capitalisation boursière?



La capitalisation boursière est la valeur marchande à un moment donné des actions en circulation d'une société cotée en bourse, étant égale au cours de l' action à ce moment-là, multiplié par le nombre d'actions en circulation .

As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.

Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.

The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.

Capitalisation boursière des entreprises dans Health Care secteur sur NASDAQ par rapport à Agile Therapeutics Inc

Que fait Agile Therapeutics Inc?

agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.

Entreprises avec capitalisation boursière similaire à Agile Therapeutics Inc